Charles Fuchs, MD: Strategies to Increase RAS Testing
What strategies can be used to increase the percentage of patients who receive recommended RAS testing?
It's really important and incumbent upon us to make sure that these data are available to all practicing oncologists. ASCO, OncLive, and other organizations are doing a good job proliferating that information, making sure that busy practitioners are aware of the data that RAS and KRAS and NRAS specifically decide for us whether a patient should get an EGFR receptor inhibitor, and that you should not be making these treatment decisions without obtaining that testing.
Unresectable Colon Cancer: Case 2
52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
